Results 311 to 320 of about 502,464 (397)

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

open access: yesArthritis &Rheumatology, EarlyView.
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon   +28 more
wiley   +1 more source

Gout and NLRP3 Inflammasome Biology

open access: yesArthritis &Rheumatology, EarlyView.
This review describes the three broad stages of acute inflammation in the context of gout: initiation, leucocyte mobilization, and self‐resolution. A typical case of a gout flare is presented. The role of the NLRP3 inflammasome in acute monosodium urate crystal–induced inflammation is reviewed in detail.
Raewyn Poulsen, Nicola Dalbeth
wiley   +1 more source

Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities

open access: yesArthritis &Rheumatology, EarlyView.
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley   +1 more source

Home - About - Disclaimer - Privacy